sitagliptin/metformin hydrochloride teva õhukese polümeerikattega tablett
teva gmbh - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 28tk; 850mg+50mg 60tk; 850mg+50mg 196tk; 850mg+50mg 14tk; 850mg+50mg 112tk; 850mg+50mg 56tk; 850mg+50mg 98tk
jamesi õhukese polümeerikattega tablett
zentiva k.s. - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 56tk; 850mg+50mg 60tk; 850mg+50mg 28tk
asigefort õhukese polümeerikattega tablett
tad pharma gmbh - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 14tk; 1000mg+50mg 56tk
asigefort õhukese polümeerikattega tablett
tad pharma gmbh - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 14tk; 850mg+50mg 200tk
jivolar õhukese polümeerikattega tablett
medochemie limited - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 1000mg+50mg 168tk; 1000mg+50mg 56tk; 1000mg+50mg 180tk; 1000mg+50mg 196tk; 1000mg+50mg 30tk; 1000mg+50mg 112tk
jivolar õhukese polümeerikattega tablett
medochemie limited - metformiin+sitagliptiin - õhukese polümeerikattega tablett - 850mg+50mg 180tk; 850mg+50mg 28tk; 0+50mg 14tk; 850mg+50mg 112tk; 850mg+50mg 30tk
metformin-ratiopharm 500 mg õhukese polümeerikattega tablett
ratiopharm gmbh - metformiin - õhukese polümeerikattega tablett - 500mg 120tk
metforal 1000 mg õhukese polümeerikattega tablett
laboratori guidotti s.p.a. - metformiin - õhukese polümeerikattega tablett - 1000mg 60tk; 1000mg 30tk; 1000mg 10tk; 1000mg 90tk; 1000mg 600tk; 1000mg 120tk
metformin-ratiopharm 850 mg õhukese polümeerikattega tablett
ratiopharm gmbh - metformiin - õhukese polümeerikattega tablett - 850mg 120tk
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.